Literature DB >> 33017033

A Potential Chinese Medicine Granule Suppressing ARDS of COVID-19: Keguan-1.

Nan-Shan Zhong1, Zi-Feng Yang2, Mei Jiang2, Jing-Yi Liang2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 33017033      PMCID： PMC7533665          DOI： 10.1007/s11655-020-3437-4

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN： 1672-0415            Impact factor:   1.978


× No keyword cloud information.
  6 in total

1.  Immunomodulatory effects of a traditional Chinese medicine with potential antiviral activity: a self-control study.

Authors:  P M K Poon; C K Wong; K P Fung; C Y S Fong; E L Y Wong; J T F Lau; P C Leung; S K W Tsui; D C C Wan; M M Y Waye; S W N Au; C B S Lau; C W K Lam
Journal:  Am J Chin Med       Date:  2006       Impact factor: 4.667

2.  Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.

Authors:  Ke Hu; Wei-Jie Guan; Ying Bi; Wei Zhang; Lanjuan Li; Boli Zhang; Qingquan Liu; Yuanlin Song; Xingwang Li; Zhongping Duan; Qingshan Zheng; Zifeng Yang; Jingyi Liang; Mingfeng Han; Lianguo Ruan; Chaomin Wu; Yunting Zhang; Zhen-Hua Jia; Nan-Shan Zhong
Journal:  Phytomedicine       Date:  2020-05-16       Impact factor: 5.340

3.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.

Authors:  Xiaobo Yang; Yuan Yu; Jiqian Xu; Huaqing Shu; Jia'an Xia; Hong Liu; Yongran Wu; Lu Zhang; Zhui Yu; Minghao Fang; Ting Yu; Yaxin Wang; Shangwen Pan; Xiaojing Zou; Shiying Yuan; You Shang
Journal:  Lancet Respir Med       Date:  2020-02-24       Impact factor: 30.700

Review 4.  Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data.

Authors:  Torsten T Bauer; Santiago Ewig; Arne C Rodloff; Eckhard E Müller
Journal:  Clin Infect Dis       Date:  2006-08-10       Impact factor: 9.079

5.  Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.

Authors:  Jia-Bo Wang; Zhong-Xia Wang; Jing Jing; Peng Zhao; Jing-Hui Dong; Yong-Feng Zhou; Guang Yang; Ming Niu; Xu Zhao; Tian-Jun Jiang; Jing-Feng Bi; Zhe Xu; Ping Zhang; Dan Wu; Zhao-Fang Bai; Yu-Ming Guo; Si-Miao Yu; Yong-Qiang Sun; Zi-Teng Zhang; Xiao-Yan Zhan; Peng-Yan Li; Jin-Biao Ding; Peng-Fei Zhao; Xue-Ai Song; Jian-Yuan Tang; Dong-Chu He; Zhu Chen; En-Qiang Qin; Rui-Lin Wang; Xiao-He Xiao
Journal:  Chin J Integr Med       Date:  2020-07-16       Impact factor: 1.978

6.  Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).

Authors:  Li Runfeng; Hou Yunlong; Huang Jicheng; Pan Weiqi; Ma Qinhai; Shi Yongxia; Li Chufang; Zhao Jin; Jia Zhenhua; Jiang Haiming; Zheng Kui; Huang Shuxiang; Dai Jun; Li Xiaobo; Hou Xiaotao; Wang Lin; Zhong Nanshan; Yang Zifeng
Journal:  Pharmacol Res       Date:  2020-03-20       Impact factor: 7.658
  6 in total
  1 in total

Review 1.  From Molecular Pathology of COVID 19 to Nigella Sativum as a Treatment Option: Scientific Based Evidence of Its Myth or Reality.

Authors:  Muhammad Atif; Farrah Naz; Junaid Akhtar; Muhammad Imran; Sidrah Saleem; Javed Akram; Muhammad Imran; Muhammad Ikram Ullah
Journal:  Chin J Integr Med       Date:  2021-09-29       Impact factor: 1.978
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.